Lawmakers have been attempting to pass legislation to delay the hemp ban or replace it with regulation since its initial passage. The ban, included in a spending bill passed by Congress last November, threatens to criminalize the vast majority of hemp products, including non-intoxicating CBD items.
Medicare Pilot Program at Risk
The Centers for Medicare and Medicaid Services recently launched a pilot program to reimburse patients for hemp-derived products, such as CBD. This initiative makes certain Medicare and Medicaid recipients eligible for up to $500 annually in reimbursements for hemp products. The program aims to evaluate whether these products can reduce overall healthcare costs. However, the hemp ban could derail these efforts.
Definition of Hemp Under Fire
The pilot program relies on the definition of hemp from the 2018 Farm Bill, which classifies hemp as cannabis with less than 0.3% delta-9 THC. The new ban, effective November 12, prohibits products containing more than 0.4 mg of any THC. According to Jonathan Miller of the US Hemp Roundtable, this would criminalize the vast majority of hemp products, including most non-intoxicating CBD.
Industry Advocates Push Back
Inesa Ponomariovaite, owner of Nesa’s Hemp, met with lawmakers this week to advocate for legal protections. She expressed concern that Congress is legislating without full understanding, noting she had to explain the endocannabinoid system to senators unfamiliar with it. This system, which interacts with cannabinoids, regulates pain, memory, and energy. Ponomariovaite emphasized that products with a broad array of cannabinoids offer stronger therapeutic effects than isolated CBD.
Legislative Efforts to Delay or Replace the Ban
Oregon Senator Ron Wyden reintroduced the Cannabinoid Safety and Regulation Act in December, aiming to replace the ban with safety regulations. Indiana Representative Jim Baird introduced a bill in January to delay the ban by two years. Miller blames political polarization for the lack of progress, stating, "Congress isn't passing anything these days."
White House Stance and Legal Challenges
President Trump has called on Congress to update the law to protect access to full-spectrum CBD products. The Trump administration has taken steps to reschedule cannabis for medical use but faces political resistance. A lawsuit against Health Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz, filed by groups including the Drug Free America Foundation, sought to block the Medicare pilot program but was denied by the court.
Focus on Contamination
Ponomariovaite argues that lawmakers should prioritize contamination over chemical composition. Hemp plants absorb toxins like mold, bacteria, and heavy metals, which can end up in products. A Forbes Health investigation found mold, yeast, and fungicide in popular CBD products. While some companies self-regulate with lab testing, quality controls are not universal. The Cannabinoid Safety and Regulation Act would enable FDA oversight.
Miller remains cautiously optimistic that Congress will act before the November deadline. Ponomariovaite warned that if the ban goes through, she will continue production but with less effective products, as she would need to isolate specific cannabinoids, removing the beneficial synergy of the whole plant.
